Accueil   Diary - News   All news GeNeuro: Cash position at 31 December 2018 and Business Review

GeNeuro: Cash position at 31 December 2018 and Business Review

 

  • Solid cash position of €16.5 million, including €7.5 million credit facility
  • Continuing partnership discussions for future development of temelimab (GNbAC1) in multiple sclerosis (MS)
  • Successful completion of high dose temelimab Phase 1 clinical study
  • Positive 6 months results from temelimab Phase 2a trial in adult Type 1 diabetes (T1D) patients
  • Ongoing preclinical development of a new antibody against Amyotrophic Lateral Sclerosis, aiming to reach the clinic in 2020

 

Geneva, Switzerland, 29 January 2019 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes, announced its cash position at 31 December 2018 and provides an updated review of its clinical developments.

 

Read the complete press release